Anti-Glargine ELISA Kit (DEIABL209)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
2x96T
Sample
serum, plasma
Species Reactivity
human
Intended Use
The Anti-Glargine ELISA kit is a dual detection sandwich assay for the determination of antibodies against glargine in serum and plasma samples. Assay employs acid charcoal pre-treatment of samples to improve drug tolerance. The assay is designed to detect human IgGs against glargine. The assay can be modified to detect other isotypes of immunoglobulins.
Storage
Store the unopened kit at 2-8°C.
Precision
Intra-assay precision (CV%): 4% - 14%. Inter-assay precision (CV%): 15%.
Detection Range
The drug tolerance is up to 100 ng/mL.
Detection Limit
67-88 ng/mL

Citations


Have you cited DEIABL209 in a publication? Let us know and earn a reward for your research.

Related Products


Glargine ELISA Kit (DEIABL229)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Effects of Insulin Degludec and Insulin Glargine U300 on Interday Glycemic Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study

DIABETES

Authors: Miura, Hiroshi; Sakaguchi, Kazuhiko; Kaneko, Akihiro; Ito, Jun; Morita, Yasuko; Yamada, Tomoko; Otowa-Suematsu, Natsu; So, Anna; Nakamura, Tomoaki; Komada, Hisako; Okada, Yuko; Hirota, Yushi; Tamori, Yoshikazu; Ogawa, Wataru

Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis

DIABETES THERAPY

Authors: Nuhoho, Solomon; Gupta, Jatin; Hansen, Brian Bekker; Fletcher-Louis, Mary; Tam Dang-Tan; Paine, Abby

Introduction Orally administered semaglutide is the first glucagon-like peptide 1 receptor agonist (GLP-1 RA) for oral administration. As head-to-head trials assessing orally administered semaglutide as an add-on to 1-2 oral antidiabetic drugs (OADs) vs other GLP-1 RAs are limited, a network meta-analysis (NMA) was performed to assess the relative efficacy and safety of orally administered semaglutide 14 mg once-daily (QD) vs injectable GLP-1 RAs in patients with type 2 diabetes inadequately controlled on 1-2 OADs. Methods A systematic literature review was conducted to identify randomised controlled trials of GLP-1 RAs in patients inadequately controlled on 1-2 OADs. Data at 26 +/- 4 weeks were extracted for efficacy and safety outcomes feasible for the NMA: change from baseline in glycated haemoglobin (HbA(1c)), weight, HbA(1c) target levels (< 7.0% and <= 6.5%), blood pressure, and any gastrointestinal adverse events specified in system organ class. Data were synthesised using NMA and a Bayesian framework. Results In total, 27 studies were included in the analyses. Orally administered semaglutide 14 mg QD was associated with significantly greater reductions in HbA(1c) vs most comparators, and numerically greater reductions vs semaglutide 0.5 mg once-weekly (QW), dulaglutide 1.5 mg QW and liraglutide 1.8 mg QD. HbA(1c) reductions with semaglutide 1 mg QW were numerically greater than those with orally administered semaglutide 14 mg QD. Reductions in body weight for orally administered semaglutide 14 mg QD were significantly greater than all comparators except semaglutide QW (both doses). Orally administered semaglutide QD 14 mg was associated with statistically similar odds of experiencing gastrointestinal adverse events vs injectable GLP-1 RAs. Conclusion Orally administered semaglutide 14 mg QD as an add-on to 1-2 OADs is one of the most efficacious GLP-1 RAs for reducing HbA(1c) and body weight at 26 +/- 4 weeks. Orally administered semaglutide 14 mg QD is well tolerated, with a safety profile in line with the GLP-1 RA class. Funding Novo Nordisk.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket